Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Ketamine for Acute Sickle Cell Pain
NCT00595530Phase 2Terminated
- Sponsor
- Connecticut Children's Medical Center
- Start
- Mar 2008
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ketamine in sickle cell disease (SCD), sponsored by Connecticut Children's Medical Center. Primary endpoint: Number of Participants With Improvement in Pain Scores of >2 Points on the Pain Scale up to 72 hours. Started Mar 2008; status: terminated.
02
Drugs
ketamine
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT00595530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00595530.